A new light of hope has surfaced for people fighting one of the most difficult types of ovarian cancer. Merck & Co. announced that their immunotherapy drug pembrolizumab, also called Keytruda, significantly improved survival rates for women with a tough type of ovarian cancer when used with chemotherapy The favourable final results of the Phase 3 KEYNOTE-B96 (ENGOT-ov65) trial represent a significant advancement in the worldwide oncology medication pipeline. 

The trial included over 640 people and compared pembrolizumab plus paclitaxel—with or without bevacizumab—to conventional treatment. For the first time, an immune checkpoint inhibitor-based regimen showed a significant overall survival advantage in all patients, regardless of PD-L1 expression. This milestone could potentially usher in a paradigm shift for patients who have previously faced limited treatment options. 

Platinum-resistant ovarian cancer is one of the most malignant gynaecologic cancers. Despite advancements in surgery and chemotherapy, approximately 70–80% of women with advanced illnesses relapse after first-line treatment, with roughly one in every four developing resistance within six months. Globally, ovarian cancer diagnoses exceed 324,000 women annually, leading to over 207,000 deaths. The burden is projected to increase by more than 40% by 2040. These findings emphasise the importance of innovation in ovarian cancer therapies and why breakthroughs like KEYNOTE-B96 are critical in the oncology medication pipeline. 

Dr Gursel Aktan, Merck's vice president of worldwide clinical development, stated that this is the first time an immune checkpoint inhibitor-based combination has effectively treated all patients with platinum-resistant illness. The safety profile of pembrolizumab was similar to earlier studies, with no new concerns raised. The findings will be presented at the ESMO Congress in 2025. 

Merck's advancements add to its broader portfolio in gynaecologic oncology. Its cooperation with AstraZeneca for olaparib (LYNPARZA) has already led to several authorised indications for ovarian cancer maintenance therapy. Meanwhile, the REJOICE-Ovarian01 study, which is assessing raludotatug deruxtecan (R-DXd) in collaboration with Daiichi Sankyo, is helping the business extend its targeted medicines portfolio. 

If regulatory bodies approve the findings, pembrolizumab-based combinations could revolutionise treatment for platinum-resistant ovarian cancer around the world. For both clinicians and patients, the trial's success highlights the growing importance of immunotherapy and combination regimens in extending survival and improving quality of life. 

As worldwide oncology research advances, this trial represents a watershed moment in changing how medicine addresses one of the most fatal tumours impacting women.